Navigation Links
Breathable treatment to help prevent asthma attacks
Date:8/31/2012

Details of a treatment that could help asthmatics fight infections that trigger 80% of asthma attacks, developed by University of Southampton spin-out company Synairgen, will be presented to European respiratory experts on Sunday 2 September.

The study provides the first evidence that boosting asthmatics' immune systems can help reduce the number of asthma attacks due to the common cold and other viral infections for the 5.4 million asthmatics in the UK.

Professor Ratko Djukanovic, a respiratory specialist at the University of Southampton and Southampton General Hospital, led the study and will present findings to the European Respiratory Society's annual congress in Vienna.

He says: "We have demonstrated the potential of a treatment, simply breathed in by the patient, which significantly reduces worsening of asthma symptoms and the patient's need to use their asthma inhaler in response to common cold infection. By presenting an immune system protein molecule, interferon beta, to the patient's lungs we can prime their body to challenge infections more effectively."

Professor Djukanovic directs the National Institute for Health Research (NIHR) Southampton Respiratory Biomedical Research Unit, one of 20 sites involved in the trial and a partnership between the University of Southampton and University Hospital Southampton NHS Foundation Trust, funded by NIHR.

He continues: "Southampton researchers, working alongside asthma patients, made the original discovery that weakened immunity amongst asthmatics was key to viral impacts; now study participants are helping us to confirm that discovery and translate it into treatments for their, and other asthmatic patients', benefit through the work of the unit."

Professor Stephen Holgate CBE, leading international asthma specialist at the University of Southampton and founder of Synairgen, says: "This is a really promising breakthrough for the future treatment of asthma and one of the most exciting developments that I have seen in years. These impressive findings across different endpoints, together with the accumulating body of evidence we have generated for other respiratory viruses such as influenza (Swine and Bird flu) and respiratory syncytial virus (RSV), strongly suggest that inhaled interferon beta has the potential to be used as a powerful broad spectrum antiviral respiratory drug in lung diseases such as COPD and pandemic flu."

Richard Marsden, Chief Executive of Synairgen, adds: "This is a great result for the development of our programme. To put this treatment's potential into context, it is estimated that in the US alone there are some 2 to 4 million difficult to treat (Step 4 and 5) adult asthma sufferers who could benefit from this therapy. We continue to analyse the wealth of data generated by this important trial and to plan the next phase of its development, ideally alongside an industry partner."


'/>"/>

Contact: Becky Attwood
r.attwood@soton.ac.uk
44-023-805-95457
University of Southampton
Source:Eurekalert

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Clinical insight improves treatment with new lung cancer drug
3. Rapid Asthma Treatment in ER May Prevent Admission
4. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
5. Breast cancer patients suffer treatment-related side effects long after completing care
6. Mayo Clinic offers newly approved treatment for acid reflux disease
7. Mobile Stroke Units Might Trim Time to Treatment
8. Breast Cancer Treatment Side Effects May Last for Years
9. Mouse Study Hints at New Path for Diabetes Treatment
10. Symptomatic behaviour in childhood strongly predicts psychiatric treatment as a young adult
11. Exercise improves quality of life during breast cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine ... of a Policy Response”, -The Rory Staunton Foundation Calls on Health & Human Services, ... Prevention of Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a new study released on ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment option called ... elastin in their face, neck, and body through a virtually pain-free, non-surgical treatment. ...
(Date:5/23/2017)... ... May 23, 2017 , ... Diagnotes, an ... a standard feature on its secure clinical communication platform. The platform allows clinicians ... depending on the type and urgency of a situation. , “We know ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... using the SPEED System™ Orthodontics, with or without a referral, from the multi-specialty ... El Segundo, CA, who is skilled in providing patients with the custom, convenient ...
(Date:5/22/2017)... , ... May 22, 2017 , ... Patients who avoid ... receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics of Westchester. This ... a variety of treatments. One or more sedation methods may be recommended based on ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
(Date:5/15/2017)... -- Enterin Inc., a privately-held CNS pharmaceutical company based in ... treat Parkinson,s disease (PD), has enrolled the first patient in ... controlled, multicenter study involving patients with PD and taking place ... a 9-to-12-month period. The first stage is open label and ... sites include Denver , Boca ...
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
Breaking Medicine Technology: